Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

KSQ-001EX for the Treatment of Patients with Advanced or Metastatic Melanoma, Recurrent Non-Small Cell Lung Carcinoma or Advanced Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Trial Status: temporarily closed to accrual

This phase I/II trial tests the safety and effectiveness of KSQ-001EX for the treatment of patients with melanoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic), non small cell lung carcinoma that has come back after a period of improvement (recurrent) or advanced recurrent or metastatic head and neck squamous cell carcinoma. KSQ-001EX takes cells from the patients tumor and genetically alters them to inactivate the SOCS1 gene. Giving KSQ-001EX may help the body response to kill tumor cells. Chemotherapy is given prior to and interleukin-2 may be given after KSQ-001EX to help the body accept the KSQ-001EX. Giving KSQ-001EX may be safe, tolerable and/or effective in treating patients with advanced or metastatic melanoma, recurrent non small cell lung carcinoma or advanced recurrent or metastatic head and neck squamous cell carcinoma.